<DOC>
	<DOCNO>NCT00512980</DOCNO>
	<brief_summary>A randomized phase II study prednisone , vinblastine , doxorubicin , gemcitabine patient intermediate stage Hodgkin 's lymphoma</brief_summary>
	<brief_title>PVAG-14 Pilot Intermediate Stages Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Histologically confirm diagnosis Hodgkin 's lymphoma 2 . Stage Clinical Stage IA , IB , IIA least one risk factor ad give Clinical Stage IIB one risk factor cd give risk factor : Large mediastinal mass ( ≥ 1/3 great thorax diameter measure chest xray ) Extranodal involvement High erythrocyte sedimentation rate ( ≥ 50 mm/h patient without Bsymptoms , ≥ 30 mm/h patient Bsymptoms ) Three involve lymph node area 3 . No prior therapy Hodgkin 's lymphoma ( exception : prephase treatment corticosteroid vincaalkaloids maximum seven day may preclude trial participation clinically indicate stag examination perform ; form prior radiotherapy preclude trial participation ) 4 . Age : 1860 year 5 . Signed informed consent understand study procedure investigational nature study 6 . Patient agree personal data tissue sample provide GHSG ( protection privacy define law ensure ) 7 . Life expectancy &gt; 3 month accord investigator judgement . 1 . Incomplete diagnosis stage disease 2 . Prior concurrent disease prevents treatment accord protocol In particular follow contraindication : Chronic obstructive pulmonary disease global insufficiency Symptomatic coronary heart disease Cardiomyopathy cardiac insufficiency ( NYHA value EF &lt; 50 % FS &lt; 25 % ) Serious uncontrolled hypertension Uncontrollable infection Leucocyte concentration &lt; 3.000/mm3 thrombocyte concentration &lt; 100.000/mm3 Creatinin clearance &lt; 60 ml/min Bilirubin &gt; 2 mg/dl GPT &gt; 100 U/l GOT &gt; 100 U/I ( exception : elevated value Hodgkin ` disease liver involvement ) HIVInfection accord HIV test Chronic acute Hepatitis 3 . HD composite lymphoma 4 . Prior chemotherapy radiation 5 . Malignant disease within last 5 year ( exception : basalioma , carcinoma situ cervix uterus , completely resect melanoma TNMpT1 ) 6 . Pregnancy , lactation , positive pregnancy test 7 . Refusal use effective contraception 8. WHO performance index &gt; 2 9 . Longterm ingestion corticosteroid ( e.g . chronic polyarthritis ) antineoplastic drug ( e.g . methotrexate ) 10 . Patient 's lack accountability , inability appreciate nature , mean consequence trial formulate his/her wish correspondingly 11 . Non compliance : Refusal blood product treatment , epilepsy , drug dependency , change residence abroad , prior cerebral injury similar circumstance appear make protocol treatment longterm followup impossible 12 . Antiepileptic treatment 13 . General intolerance protocol medication 14 . Any contraindication study medication accord summary product information 15 . Simultaneous participation another clinical 16 . Institutionalization law 17 . Relation dependence sponsor ` representative / trialist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>intermediate stage</keyword>
</DOC>